{
    "nctId": "NCT02820961",
    "briefTitle": "Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer",
    "officialTitle": "A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Estrogen Receptor Positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 61,
    "primaryOutcomeMeasure": "Cmax, maximum plasma concentration",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal female patients\n* Histologically or cytologically confirmed ER+ breast cancer at initial diagnosis and have locally recurrent or metastatic disease that has progressed to where the patient is a candidate to receive exemestane as determined by the Investigator\n* Patients receiving palliative radiation at the non-target lesions must be clinically stable prior to receiving the first dose of study treatment\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Patient must have acceptable, applicable laboratory requirements\n* Patients may have a history of brain metastasis provided certain protocol criteria are met\n* Able to understand and give written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Rapidly progressive or life-threatening metastases\n* Inability to swallow oral medications or gastrointestinal (GI) malabsorption syndromes\n* History of significant GI surgery as determined by Investigator\n* A medical condition that precludes adequate study treatment or increases patient risk\n* Currently enrolled in (or completed within 30 days prior to study drug administration) another investigational drug study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}